
|Articles|April 1, 2004
Informed consent cornerstone of research
Dr. Smarts wants to start performing clinical research studies in his office. He assumes that such research will bring him the press notoriety that will boost his lagging dermatology practice. Dr. Smarts begins to evaluate a new substance for the treatment of psoriasis not approved by the FDA. He verbally tells his patients they are research "guinea pigs"; he lets them know he is able to obtain the as-of-now unobtainable material from a local compounding pharmacy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
5














